NEW YORK, September 24, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on the following equities: CME Group Inc.  (NASDAQ: CME), Commerce Bancshares, Inc. (NASDAQ: CBSH), Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), Exelixis, Inc. (NASDAQ: EXEL), CTI BioPharma Corp. (NASDAQ: CTIC). On Wednesday, September 23, 2015, NASDAQ ended at 4,752.74, down 0.08%, Dow Jones declined 0.31% to finish the day at 16,279.89, and the S&P closed at 1,938.76, down 0.20%. Register for your complimentary reports at the links given below.

--

CME Group Inc.  

--

CME Group Inc.'s stock edged higher by 0.58% to close Wednesday's session at USD 91.24. The stock recorded a trading volume of 0.67 million shares, which was below its 50-day daily average volume of 1.65 million shares. Over the last three days, CME Group Inc.'s shares have advanced 0.93%, but in the past one week the stock has moved down 4.33%. On a compounded total return basis, the stock has returned 0.09% in the past one month, but has shown a negative return of 3.24% in the past three months. The company is trading at a price to earnings ratio of 25.85, compared to a historical PE ratio of 26.43. Further, the stock is at a price to book ratio of 1.44, while the historical PB ratio is near to 1.42. Additionally, the stock is trading at a price to cash flow ratio of 18.60 and price to sales ratio of 9.44. Sign up and read the free notes on CME at:  http://www.aciassociation.com/CME.pdf

--

Commerce Bancshares Inc.  

--

The stock of Commerce Bancshares Inc. gained 0.91% to close Wednesday's session at USD 44.48. A trading volume of 0.65 million shares was recorded, which was greater than its 150-day daily average volume of 0.53 million shares. Over the last five days Commerce Bancshares Inc.'s shares have declined by 1.48% and in the past one month the stock has lost 1.92%. The stock has returned 5.44% in the past six months and 4.28% in the last one year, on a compounded total return basis. Further, the company is trading at a price to earnings ratio of 16.68 and at a price to book ratio of 1.92. Additionally, the stock is trading at a price to cash flow ratio of 11.68 and price to sales ratio of 3.75. Register for free on ACI Association and access the latest research on CBSH at:  http://www.aciassociation.com/CBSH.pdf

--

Conatus Pharmaceuticals Inc.  

--

Conatus Pharmaceuticals Inc.'s stock increased by 15.73% to close Wednesday's session at USD 5.74. The company's shares fluctuated in the range of USD 5.12 and USD 6.15. A total of 6.81 million shares exchanged hands, which surpassed its 50-day daily average volume of 0.28 million shares and was above its 52-week average volume of 0.46 million shares. Over the last three days Conatus Pharmaceuticals Inc.'s shares have advanced 23.71% and in the past one week the stock has moved up 29.28%. The stock has returned 43.50% in the past one month but has shown a negative return of 2.05% in the last three months, on a compounded total return basis. The company is trading at a market capitalization of USD 113.19 million. The complete research on CNAT is available for free at:  http://www.aciassociation.com/CNAT.pdf

--

Exelixis Inc.  

--

Exelixis Inc.'s stock added 0.16% to close Wednesday's session at USD 6.25. The company's shares oscillated between USD 6.09 and USD 6.33. The stock recorded a trading volume of 4.44 million shares, which was above its 52-week average volume of 4.29 million shares. Over the last five days Exelixis Inc.'s shares have advanced 0.64% and in the past one month the stock has gained a momentum of 19.05%. In addition, over the last three months the stock has gained 62.76% and year to date the shares have picked up 334.03%. The company has returned 19.05% in the past one month and 293.08% in the past one year, on a compounded total return basis. The company is trading with a market capitalization of USD 1,408.94 million. Additionally, the stock is trading at a price to sales ratio of 45.41. Free in-depth research on EXEL is available at:  http://www.aciassociation.com/EXEL.pdf

--

CTI BioPharma Corp  

--

CTI BioPharma Corp's stock advanced 9.03% to close Wednesday's session at USD 1.57. The share price vacillated between USD 1.53 and USD 1.61. The stock recorded a trading volume of 2.52 million shares, which was above its 50-day daily average volume of 1.16 million shares and above its 52-week average volume of 2.36 million shares. Over the last three days CTI BioPharma Corp's shares have advanced 3.97% and in the past one week the stock has moved up 1.29%. Moreover, in the last six months the stock has lost 17.80% and year to date the shares have shed 33.47%. On a compounded total return basis, the stock has shown a negative return of 19.07% in the last half a year and of 40.08% in the past one year. Further, the stock is trading at a price to sales ratio of 4.64. The complimentary notes on CTIC can be downloaded in PDF format at:  http://www.aciassociation.com/CTIC.pdf

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA(R) charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com